You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClocortolone
Accession NumberDB00838  (APRD00877)
TypeSmall Molecule
GroupsApproved
DescriptionClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Structure
Thumb
Synonyms
9-chloro-6alpha-Fluoro-11beta,21-dihydroxy-16alpha-methyl-1,4-pregnadien-3,20-dione
9-chloro-6alpha-Fluoro-16alpha-methyl-1,4-pregnadiene-11beta,21-diol-3,20-dione
Clocortolon
Clocortolona
Clocortolone
Clocortolonum
External Identifiers
  • SH 863
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Clocortolone PivalateCream.001 g/gTopicalDr. Reddy's Laboratories Inc2014-02-17Not applicableUs
ClodermCream.001 g/gTopicalCoria Laboratories1977-08-222016-05-01Us
ClodermCream.001 g/gTopicalPromius Pharma, LLC1977-08-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Clocortolone acetate
4258-85-9
Thumb
  • InChI Key: ARPLCFGLEYFDCN-CDACMRRYSA-N
  • Monoisotopic Mass: 452.1765799
  • Average Mass: 452.95
DBSALT000939
Clocortolone caproate
4891-71-8
Thumb
  • InChI Key: MMTRTBFDFNRBQO-ANHDKODLSA-N
  • Monoisotopic Mass: 508.2391802
  • Average Mass: 509.06
DBSALT001838
Clocortolone pivalate
34097-16-0
Thumb
  • InChI Key: SXYZQZLHAIHKKY-GSTUPEFVSA-N
  • Monoisotopic Mass: 494.2235301
  • Average Mass: 495.03
DBSALT001365
Categories
UNIIN8ZUB7XE0H
CAS number4828-27-7
WeightAverage: 410.907
Monoisotopic: 410.166015296
Chemical FormulaC22H28ClFO4
InChI KeyYMTMADLUXIRMGX-RFPWEZLHSA-N
InChI
InChI=1S/C22H28ClFO4/c1-11-6-13-14-8-16(24)15-7-12(26)4-5-21(15,3)22(14,23)18(28)9-20(13,2)19(11)17(27)10-25/h4-5,7,11,13-14,16,18-19,25,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,18+,19-,20+,21+,22+/m1/s1
IUPAC Name
(1R,2S,8S,10S,11S,13R,14S,15S,17S)-1-chloro-8-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@@H](C)[[email protected]](C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1(Cl)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Pharmacology
IndicationFor short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Structured Indications
PharmacodynamicsLike other topical corticosteroids, clocortolone has anti-inflammatory, antipruritic, and vasoconstrictive properties. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Clocortolone is a moderate potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mechanism of actionThe precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. These enzyme transcriptional changes are mediated by the drug binding first to the glucocorticoid receptor. This complex can migrate to the cell nucleus which then binds to DNA initiating genetic activation and repression of various genes.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionTopical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may also increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Metabolized, primarily in the liver, and then excreted by the kidneys.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityTopically applied clocortolone can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Clocortolone is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clocortolone.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Clocortolone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Clocortolone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Clocortolone.Approved
AldesleukinClocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Clocortolone is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Clocortolone can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Clocortolone can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clocortolone.Approved
AmiodaroneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BClocortolone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Clocortolone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Clocortolone.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Clocortolone.Approved, Investigational
AprepitantThe serum concentration of Clocortolone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Clocortolone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clocortolone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Clocortolone.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Clocortolone.Approved, Investigational
BazedoxifeneThe serum concentration of Clocortolone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideClocortolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Clocortolone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Clocortolone.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Clocortolone.Investigational
Bismuth SubcitrateThe bioavailability of Clocortolone can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Clocortolone can be increased when it is combined with Boceprevir.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Clocortolone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Clocortolone.Investigational
BumetanideClocortolone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Clocortolone.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Clocortolone can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Clocortolone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Clocortolone.Experimental
CDX-110The risk or severity of adverse effects can be increased when Clocortolone is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clocortolone.Approved, Investigational
CeritinibClocortolone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Clocortolone.Approved, Vet Approved
ChlorothiazideClocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Clocortolone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneClocortolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Clocortolone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Clocortolone.Approved
CobicistatThe serum concentration of Clocortolone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Clocortolone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated Equine EstrogensThe serum concentration of Clocortolone can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Clocortolone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Clocortolone.Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Clocortolone.Investigational
DarunavirThe serum concentration of Clocortolone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Clocortolone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Clocortolone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Clocortolone.Approved, Vet Approved
DienestrolThe serum concentration of Clocortolone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Clocortolone can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.Approved
DihydrotestosteroneClocortolone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DonepezilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Clocortolone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Clocortolone.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Clocortolone.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Clocortolone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Clocortolone is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Clocortolone can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Clocortolone.Approved
EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Clocortolone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.Approved
Etacrynic acidClocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Clocortolone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Clocortolone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Clocortolone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Clocortolone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Clocortolone.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Clocortolone.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Clocortolone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Clocortolone.Approved
FenthionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Clocortolone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Clocortolone.Vet Approved
FluoxymesteroneClocortolone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Clocortolone.Approved, Investigational
FosaprepitantThe serum concentration of Clocortolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideClocortolone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Clocortolone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Clocortolone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Clocortolone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Clocortolone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Clocortolone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Clocortolone.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Clocortolone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Clocortolone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone.Approved, Investigational
HydrochlorothiazideClocortolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideClocortolone may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Clocortolone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Clocortolone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Clocortolone.Approved
IdelalisibThe serum concentration of Clocortolone can be increased when it is combined with Idelalisib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Clocortolone.Approved
IndapamideClocortolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Clocortolone can be increased when it is combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Clocortolone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Clocortolone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 225.Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Clocortolone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Clocortolone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clocortolone.Withdrawn
ItraconazoleThe serum concentration of Clocortolone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Clocortolone.Experimental
KetoconazoleThe serum concentration of Clocortolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Clocortolone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clocortolone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Clocortolone.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Clocortolone.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Clocortolone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Clocortolone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clocortolone.Approved
LumacaftorThe serum concentration of Clocortolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Clocortolone.Approved, Investigational
MagaldrateThe bioavailability of Clocortolone can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Clocortolone can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Clocortolone can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Clocortolone.Approved
Magnesium TrisilicateThe bioavailability of Clocortolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Clocortolone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Clocortolone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Clocortolone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Clocortolone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Clocortolone.Approved
MestranolThe serum concentration of Clocortolone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone.Withdrawn
MethallenestrilThe serum concentration of Clocortolone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Clocortolone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideClocortolone may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneClocortolone may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneClocortolone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Clocortolone can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Minaprine.Approved
MitotaneThe serum concentration of Clocortolone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Clocortolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Clocortolone.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clocortolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Clocortolone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Clocortolone.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clocortolone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Clocortolone.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Clocortolone.Investigational
NefazodoneThe serum concentration of Clocortolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Clocortolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Clocortolone.Approved
NevirapineThe serum concentration of Clocortolone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Clocortolone is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Clocortolone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clocortolone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Clocortolone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Clocortolone.Vet Approved
OxandroloneClocortolone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone.Approved
OxymetholoneClocortolone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Clocortolone.Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Clocortolone.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Clocortolone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Clocortolone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Clocortolone.Approved, Vet Approved
PhenytoinThe serum concentration of Clocortolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Clocortolone.Approved, Investigational
PiretanideClocortolone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Clocortolone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Clocortolone.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Clocortolone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideClocortolone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Clocortolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Clocortolone can be decreased when it is combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Clocortolone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Clocortolone.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Clocortolone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Clocortolone can be increased when it is combined with Quinestrol.Approved
QuinethazoneClocortolone may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rabies vaccine.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Clocortolone.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Clocortolone.Experimental, Investigational
RifabutinThe serum concentration of Clocortolone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Clocortolone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Clocortolone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Clocortolone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Clocortolone.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rosoxacin.Approved
S EquolThe serum concentration of Clocortolone can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clocortolone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clocortolone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Clocortolone.Approved
SaquinavirThe serum concentration of Clocortolone can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Clocortolone can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Clocortolone.Approved, Investigational
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Clocortolone.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Clocortolone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Clocortolone.Investigational
St. John's WortThe serum concentration of Clocortolone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololClocortolone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clocortolone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Clocortolone.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Clocortolone.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Clocortolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Clocortolone.Approved
TelithromycinThe serum concentration of Clocortolone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Clocortolone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Clocortolone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Clocortolone.Approved
TestosteroneClocortolone may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Clocortolone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Clocortolone.Approved
TiboloneThe serum concentration of Clocortolone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Clocortolone.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Clocortolone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Clocortolone.Approved
TorasemideClocortolone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Clocortolone.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Clocortolone is combined with Trichlorfon.Vet Approved
TrichlormethiazideClocortolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clocortolone.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Clocortolone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Clocortolone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Clocortolone.Investigational, Withdrawn
VoriconazoleThe serum concentration of Clocortolone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinClocortolone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Clocortolone.Approved
ZeranolThe serum concentration of Clocortolone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Clocortolone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Clocortolone.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesD07AB21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (167 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9737
Caco-2 permeable+0.8054
P-glycoprotein substrateSubstrate0.7404
P-glycoprotein inhibitor INon-inhibitor0.7095
P-glycoprotein inhibitor IINon-inhibitor0.8814
Renal organic cation transporterNon-inhibitor0.8141
CYP450 2C9 substrateNon-substrate0.8412
CYP450 2D6 substrateNon-substrate0.8977
CYP450 3A4 substrateSubstrate0.7374
CYP450 1A2 substrateNon-inhibitor0.9164
CYP450 2C9 inhibitorNon-inhibitor0.9119
CYP450 2D6 inhibitorNon-inhibitor0.9061
CYP450 2C19 inhibitorNon-inhibitor0.9182
CYP450 3A4 inhibitorInhibitor0.6251
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.857
Ames testNon AMES toxic0.8537
CarcinogenicityNon-carcinogens0.8855
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9619
hERG inhibition (predictor II)Non-inhibitor0.5411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Dow pharmaceutical sciences inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical.001 g/g
Prices
Unit descriptionCostUnit
Cloderm 0.1% Cream 45 gm Tube140.98USD tube
Cloderm 0.1% cream3.64USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.015 mg/mLALOGPS
logP2.73ALOGPS
logP2.47ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area74.6 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity105.74 m3·mol-1ChemAxon
Polarizability41.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Chlorohydrin
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alkyl chloride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Ali A, Balkovec JM, Greenlee M, Hammond ML, Rouen G, Taylor G, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Forrest MJ, Carballo-Jane E, Luell S, Lowitz K, Visco D: Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat. Bioorg Med Chem. 2008 Aug 15;16(16):7535-42. doi: 10.1016/j.bmc.2008.07.037. Epub 2008 Jul 20. [PubMed:18691892 ]
  2. Buchwald P: Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008 Feb;73(2):193-208. Epub 2007 Oct 11. [PubMed:18022656 ]
  3. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23